Get the Stockscreener App
1.32
0.00%
0.00
After Hours:
1.30
-0.02
-1.52%
Opko Health Inc stock is traded at $1.32, with a volume of 1.89M.
It is up +0.00% in the last 24 hours and down -2.94% over the past month.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
See More
Previous Close:
$1.32
Open:
$1.34
24h Volume:
1.89M
Relative Volume:
0.57
Market Cap:
$1.09B
Revenue:
$711.41M
Net Income/Loss:
$-133.73M
P/E Ratio:
-6.9474
EPS:
-0.19
Net Cash Flow:
$-199.99M
1W Performance:
+3.94%
1M Performance:
-2.94%
6M Performance:
-10.20%
1Y Performance:
+5.60%
1-Day Range:
$1.30
$1.34
1-Week Range:
$1.26
$1.34
52-Week Range:
$1.19
$2.035
Opko Health Inc Stock (OPK) Company Profile
Name
Opko Health Inc
Sector
Industry
Phone
305-575-4181
Address
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.32 | 1.09B | 711.41M | -133.73M | -199.99M | -0.19 |
|
TMO
Thermo Fisher Scientific Inc
|
405.46 | 156.49B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.54 | 145.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
536.34 | 42.30B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
118.01 | 34.24B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
157.59 | 27.64B | 15.50B | 1.33B | 2.16B | 7.34 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-25 | Initiated | JP Morgan | Neutral |
| Jun-29-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Jan-24-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-21-21 | Initiated | Ladenburg Thalmann | Buy |
| Nov-25-19 | Initiated | Piper Jaffray | Overweight |
| Mar-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-14-17 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-21-16 | Reiterated | Standpoint Research | Buy |
| Jun-03-16 | Initiated | Standpoint Research | Buy |
| Mar-31-16 | Reiterated | Barrington Research | Outperform |
| Oct-16-15 | Initiated | JP Morgan | Overweight |
| Sep-11-15 | Downgrade | Jefferies | Buy → Hold |
| Mar-03-15 | Downgrade | Oppenheimer | Outperform → Perform |
| May-12-14 | Reiterated | Oppenheimer | Outperform |
| Mar-14-14 | Initiated | Oppenheimer | Outperform |
| Nov-13-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-30-13 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-22-12 | Initiated | Barrington Research | Outperform |
| Dec-01-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jul-14-11 | Initiated | Ladenburg Thalmann | Buy |
View All
Opko Health Inc Stock (OPK) Latest News
Shareholders in OPKO Health (NASDAQ:OPK) have lost 51%, as stock drops 6.5% this past week - simplywall.st
Here's Why You Should Retain OPKO Health Stock in Your Portfolio - MSN
Quote - OPKO Health, Inc.
Bone Cancer Drugs Market Set to Witness Significant Growth - openPR.com
Bank of America Corp DE Has $855,000 Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
OPKO Health: Strong Pipeline Of Drugs, But Not Rushing To Buy (NASDAQ:OPK) - Seeking Alpha
ModeX assembles advisory board for antibody development By Investing.com - Investing.com India
ModeX assembles advisory board for antibody development - Investing.com
OPKO Health's ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development - The Manila Times
OPKO Health's (OPK) ModeX Therapeutics Forms Scientific Advisory Board - StreetInsider
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development - GlobeNewswire
OPKO Health’s ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development - GlobeNewswire Inc.
Nuveen Asset Management LLC Boosts Holdings in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
BNP Paribas Financial Markets Cuts Position in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
OPKO Health, Inc. (NASDAQ:OPK) Shares Purchased by Two Sigma Investments LP - MarketBeat
Peptide Therapeutics Market Growth Set to Surge Significantly - openPR.com
Opko health outlines $675M-$685M revenue guidance for 2025 amid strategic initiatives - MSN
Bone Cancer Drugs Market in 2025-2032 Detailed Study Analysis - openPR.com
BNP Paribas Financial Markets Sells 195,118 Shares of OPKO Health, Inc. (NASDAQ:OPK) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 8,064 Shares of OPKO Health, Inc. (NASDAQ:OPK) - Defense World
Q2 EPS Estimates for OPKO Health Reduced by Zacks Research - MarketBeat
Millennium Management LLC Boosts Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Deutsche Bank AG Grows Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK) - Defense World
Opko Health grants stock options, approves bonuses - Investing.com India
Opko Health grants stock options, approves bonuses By Investing.com - Investing.com Nigeria
Opko Health Grants Stock Options and Bonuses - TipRanks
OPKO Health (OPK) Rises with Promising Oncology Developments - GuruFocus
SA Asks: What are the best oncology stocks right now? - Seeking Alpha
Millennium Management LLC Boosts Holdings in OPKO Health, Inc. (NASDAQ:OPK) - Defense World
Down Syndrome Market: Epidemiology, Therapies, Companies, - openPR.com
What OPKO Health, Inc.'s (NASDAQ:OPK) P/S Is Not Telling You - simplywall.st
Hyperparathyroidism Treatment Market: Effective Treatment - openPR.com
OPKO Health, Inc. (NASDAQ:OPK) Shares Acquired by Lazard Asset Management LLC - MarketBeat
Opko Health at BioConnect: Strategic Shifts and Financial Insights By Investing.com - Investing.com India
Opko Completes Prolor Deal - Medical Product Outsourcing
Mercer Global Advisors Inc. ADV Grows Stake in OPKO Health, Inc. (NASDAQ:OPK) - Defense World
Strong week for OPKO Health (NASDAQ:OPK) shareholders doesn't alleviate pain of three-year loss - Yahoo Finance
Esoteric Testing Market Set to Witness Significant Growth - openPR.com
OPKO Health to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Dimensional Fund Advisors LP Lowers Position in OPKO Health, Inc. (NASDAQ:OPK) - Defense World
Opko Health Inc Stock (OPK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opko Health Inc Stock (OPK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 08 '25 |
Buy |
1.48 |
125,000 |
184,650 |
213,876,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 01 '25 |
Buy |
1.65 |
100,000 |
164,850 |
213,751,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 28 '25 |
Buy |
1.70 |
150,000 |
254,385 |
213,651,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 17 '25 |
Buy |
1.74 |
200,000 |
347,820 |
213,501,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Feb 28 '25 |
Buy |
1.71 |
67,434 |
115,312 |
213,301,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 28 '25 |
Buy |
1.47 |
47,537 |
70,060 |
213,234,014 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 17 '25 |
Buy |
1.47 |
150,000 |
220,425 |
213,186,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 15 '25 |
Buy |
1.48 |
500,000 |
740,850 |
213,036,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Dec 13 '24 |
Buy |
1.59 |
125,000 |
199,375 |
212,536,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Dec 11 '24 |
Buy |
1.56 |
500,000 |
781,050 |
212,411,477 |
1.01%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):